The earnings call presented a strong performance in MRD business profitability, improved gross margins, and a solid cash position, with a raised full-year guidance. However, there were challenges in Immune Medicine revenue and uncertainties in regulatory acceptance of MRD as an endpoint.

Company Guidance

During Adaptive Biotechnologies' third quarter 2025 earnings call, the company reported a robust financial performance and provided updated guidance. The MRD business achieved significant milestones, including $7 million in adjusted EBITDA and becoming cash flow positive. MRD revenue rose by 52% year-over-year, driven by a 38% increase in test volumes and an 83% growth in clonoSEQ clinical revenue. The company conducted over 27,100 tests, with a notable increase in U.S. clonoSEQ ASP to over $1,340 per test. They ended the quarter with $217 million in cash, a reduction in cash burn by 51% year-over-year. Consequently, Adaptive raised its full-year MRD revenue guidance to $202-$207 million and lowered its operating expense and cash burn forecasts. The company continues to focus on operational efficiencies, with total company sequencing gross margin improving to 66% and operating expenses remaining stable.

MRD Business Profitability and Growth

The MRD business delivered adjusted EBITDA of $7 million, became cash flow positive, and grew revenue by 52% year-over-year. clonoSEQ clinical revenue grew 83% year-over-year with a test volume increase of 38%.

Improved Gross Margins

Total company sequencing gross margin improved 10 percentage points year-over-year to 66%.

Strong Cash Position

Cash burn reduced by 51% compared to last year, ending the quarter with $217 million in cash.

Full Year Guidance Raised

Full-year MRD revenue guidance increased to $202 million to $207 million, with expectations of approximately 104,000 tests for the year.

Expansion of Reimbursement Footprint

Achieved first large commercial payer coverage in DLBCL and two major payers in CLL, bringing total CLL covered lives to over 260 million.

Adaptive Biotechnologies (ADPT) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

ADPT Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Feb 17, 2026	2025 (Q4)	-0.18 / -	-0.23	―	―	―
Nov 05, 2025	2025 (Q3)	-0.15 / 0.06	-0.22	127.27% (+0.28)
Aug 05, 2025	2025 (Q2)	-0.24 / -0.17	-0.31	45.16% (+0.14)
May 01, 2025	2025 (Q1)	-0.29 / -0.20	-0.33	39.39% (+0.13)
Feb 11, 2025	2024 (Q4)	-0.26 / -0.23	-0.48	52.08% (+0.25)
Nov 07, 2024	2024 (Q3)	-0.29 / -0.22	-0.35	37.14% (+0.13)
Aug 01, 2024	2024 (Q2)	-0.33 / -0.31	-0.33	6.06% (+0.02)
May 07, 2024	2024 (Q1)	-0.35 / -0.33	-0.4	17.50% (+0.07)
Feb 14, 2024	2023 (Q4)	-0.33 / -0.48	-0.28	-71.43% (-0.20)
Nov 09, 2023	2023 (Q3)	-0.34 / -0.35	-0.32	-9.37% (-0.03)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

ADPT Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Nov 05, 2025	$17.59	$15.56	-11.54%
Aug 05, 2025	$11.05	$11.69	+5.79%
May 01, 2025	$7.36	$9.84	+33.70%
Feb 11, 2025	$7.80	$7.55	-3.21%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Adaptive Biotechnologies Corp (ADPT) report earnings?

Adaptive Biotechnologies Corp (ADPT) is schdueled to report earning on Feb 17, 2026, After Close (Confirmed).

What is Adaptive Biotechnologies Corp (ADPT) earnings time?

Adaptive Biotechnologies Corp (ADPT) earnings time is at Feb 17, 2026, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is ADPT EPS forecast?

ADPT EPS forecast for the fiscal quarter 2025 (Q4) is -0.18.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing